Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
AIDS Res Hum Retroviruses. 2012 Apr;28(4):400-4. doi: 10.1089/AID.2011.0240. Epub 2011 Sep 27.

Evaluating immune correlates in HIV type 1 vaccine efficacy trials: what RV144 may provide.

Author information

  • 1MHRP:HJF, Rockville, Maryland 20850, USA. mrolland@hivresearch.org

Abstract

Since the RV144 vaccine combination showed efficacy in a Phase III trial, it provides an opportunity to generate hypotheses about the immune responses necessary for protection against HIV-1 infection, and these results could help devise vaccine candidates with higher efficacy. Here we describe how researchers can determine the correlates of immune protection for an HIV/AIDS vaccine, particularly in the context of the RV144 trial, and we discuss the terminology used to describe correlates and surrogates.

PMID:
21902593
[PubMed - indexed for MEDLINE]
PMCID:
PMC3316118
Free PMC Article

Images from this publication.See all images (1)Free text

FIG. 1.
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for Mary Ann Liebert, Inc. Icon for PubMed Central
    Loading ...
    Write to the Help Desk